Neurology 1010 - Neurology Alert - Oct 01, 2006

Target Audience:

This activity is intended for the neurologist.

Accreditation:

AHC Media is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation:

AHC Media designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty

Physician Editor
Matthew E. Fink, MD
Vice Chairman
Professor of Clinical Neurology
Weill Medical College
Chief of Division
Stroke and Critical Care Neurology
NewYork-Presbyterian Hospital

Peer Reviewer
M. Flint Beal, MD
Professor and Chairman
Department of Neurology
Cornell University Medical College
New York, NY

Assistant Editors
Dana Leifer, MD
Associate Professor
Neurology
Weill Medical College
Cornell University

Michael Rubin, MD
Professor of Clinical Neurology
NewYork Presbyterian Hospital
Cornell Campus

Norman R. Relkin, MD, PhD
Associate Professor
Clinical Neurology and Neuroscience
NewYork Presbyterian Hospital
Cornell Campus

Claire Henchcliffe, MD, DPhil
Assistant Professor
Department of Neurology
Weill Medical College
Cornell University

Dara G. Jamieson, MD
Associate Professor
Clinical Neurology Director
Weill Medical College;
Neurovascular Ultrasound
Headache Center

Author
Melissa J. Nirenberg, MD, PhD
Assistant Professor
Neurology and Neuroscience
Weill Cornell Medical College

Subjects:

  • More Good News for Stroke Prevention — Statins and ACE Inhibitors Really Work!
  • Genetic Risk Factors for Myopathies Induced by Lipid-Lowering Drugs
  • Cluster Headaches
  • Is Ginkgo Biloba Comparable to Donepezil for Treating AD?
  • Impulse Control Disorders in Parkinson's Disease: Too Much of a Good Thing?
  • α-Synuclein Promoter Variability Affects Risk for Parkinson's Disease
  • Cardiac Surgery and Cerebrovascular Disease: What are the Risks, Options?

Objectives:

  • Present current scientific data regarding diagnosis and treatment of neurologic disease, including stroke, Alzheimer?s disease, transient ischemic attack, and coma
  • Discuss the pathogenesis and treatment of pain
  • Present basic science lessons in brain function
  • Discuss information regarding new drugs for commonly diagnosed diseases and new uses for traditional drugs
  • Discuss nonclinical issues of importance to neurologists, such as the right to die and the physician?s legal obligation to patients with terminal illness

Financial Disclosure:

Neurology Alert's physician editor, Matthew E. Fink, MD, reports no consultant, stockholder, speaker's bureau, research, or other relationships related to this field of study. Peer reviewer M. Flint Beal, MD, reports no consultant, stockholder, speaker's bureau, research, or other financial relationship with any company having ties to this field of study. Assistant editor Dana Leifer, MD and author Melissa J. Nirenberg, MD, PhD report no financial relationship relevant to this field of study. Assistant editor Michael Rubin, MD is on the speaker's bureau for Athena Diagnostics, and does research for Pfizer and Merck. Assistant editor Norman R. Relkin, MD, PhD is on the speaker's bureau for Pfizer, Eisai, and Athena Diagnostics, and does research for Pfizer and Merck. Assistant editor Claire Henchcliffe, MD, DPhil is on the speaker's bureau for GlaxoSmithKline, Teva/Eisai, and Boehringer Ingelheim. Assistant editor Dara G. Jamieson, MD is a consultant for Boehringer Ingelheim and Merck, and is on the speaker's bureau for Boehringer Ingelheim, Merck, Ortho-McNeil, and Pfizer.

Copyright 2006 AHC Media. All rights reserved.